Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-30, Stock:LLY, The news for the past five days is as follows:
2018-04-23: NEWS1: FDA panel against higher dose of Lilly-Incyte arthritis drug.NEWS2: FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose.NEWS3: FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose.NEWS4: Pre-Market Earnings Report for April 24, 2018 :  VZ, KO, MMM, LMT, UTX, CAT, LLY, NEE, BIIB, TRV, SHW, FCX.NEWS5: Pre-Market Earnings Report for April 24, 2018 :  VZ, KO, MMM, LMT, UTX, CAT, LLY, NEE, BIIB, TRV, SHW, FCX.NEWS6: Analysts’ Recommendations for Eli Lilly & Co. on April 20.NEWS7: Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN.NEWS8: Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN.NEWS9: Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected.NEWS10: Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN.NEWS11: Upcoming Earnings: CAT, LLY And BA Report This Week.NEWS12: Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings.NEWS13: Merck’s Relebactam Met Primary Endpoints in Phase 3 Study.NEWS14: What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings.NEWS15: Elanco Announces Addition of Chief Financial Officer.
2018-04-24: NEWS1: Eli Lilly Lures Bain, Advent on Animal Health Sale.NEWS2: Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?.NEWS3: Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?.NEWS4: Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018.NEWS5: Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower.NEWS6: Eli Lilly Tops On Diabetes, Chemo Strength But A Key Drug Lagged.NEWS7: Ozempic Could Be Potential Driver for Novo Nordisk in 2018.NEWS8: Dow Skids and Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles.NEWS9: Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?.NEWS10: Express Scripts targets Amgen, Lilly migraine drugs in pricing shift.NEWS11: Why the market is blowing off what has been a really good earnings season.NEWS12: Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles.NEWS13: Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug.NEWS14: Stocks Trade Lower as 10-Year Yield Hits 3%.NEWS15: Is There An Opportunity With Eli Lilly and Company’s (NYSE:LLY) 26% Undervaluation?.NEWS16: Stocks Turn Lower as 10-Year Yield Hits 3%.NEWS17: Eli Lilly's profit beats on strong sales of diabetes, cancer drugs.NEWS18: Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up.NEWS19: Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up.NEWS20: Stocks Rise as Earnings Propel Wall Street Higher.NEWS21: Health Care Sector Update for 04/24/2018: LLY, INCY, BIIB, CNC.NEWS22: Health Care Sector Update for 04/24/2018: LLY, INCY, BIIB, CNC.NEWS23: Stocks to Watch: Alphabet, Amazon, Caterpillar, Coca-Cola, Travelers, Lockheed, United Technologies, 3M.NEWS24: Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?.NEWS25: Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?.NEWS26: Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View.NEWS27: Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View.NEWS28: Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18.NEWS29: Lilly (LLY) Tops on Q1 Earnings, Raises &apos;18 View, Stock Up.NEWS30: Eli Lilly CEO Says Insulin Business Continues to Do Well.NEWS31: Eli Lilly CEO Says Insulin Business Continues to Do Well.NEWS32: Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance.NEWS33: Sohn Conference Sees Gundlach Wanting to Short Facebook.NEWS34: Henry Schein to Merge Animal Health with Vets First Choice.NEWS35: Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View.NEWS36: Earnings Reaction History: Eli Lilly & Co., 36.4% Follow-Through Indicator, 2.3% Sensitive.NEWS37: Earnings Reaction History: Eli Lilly & Co., 36.4% Follow-Through Indicator, 2.3% Sensitive.NEWS38: Eli Lilly, Incyte shares drop after mixed FDA drug recommendation.NEWS39: Eli Lilly Tops Earnings Views, Raises Guidance.NEWS40: Eli Lilly CEO: We're beginning a new phase of growth.NEWS41: Eli Lilly raises 2018 profit view after quarterly earnings, sales beat expectations.NEWS42: Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback.NEWS43: Eli Lilly shares up after earnings beat.NEWS44: Lilly: 1Q Earnings Snapshot.NEWS45: Drugmaker Eli Lilly posts quarterly profit.NEWS46: Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance.NEWS47: AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies.NEWS48: Eli Lilly And Co. Q1 18 Earnings Conference Call At 9:00 AM ET.NEWS49: Eli Lilly And Co. Q1 18 Earnings Conference Call At 9:00 AM ET.NEWS50: Lilly Q1 Results Beat Estimates; Raises 2018 Outlook.NEWS51: Lilly Q1 Results Beat Estimates; Raises 2018 Outlook.NEWS52: PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA.NEWS53: PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA.NEWS54: FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis.
2018-04-25: NEWS1: Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales.NEWS2: Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales.NEWS3: Edited Transcript of LLY earnings conference call or presentation 24-Apr-18 1:00pm GMT.NEWS4: HDV, UPS, LLY, D: Large Outflows Detected at ETF.NEWS5: HDV, UPS, LLY, D: Large Outflows Detected at ETF.NEWS6: Sanofi’s 1Q18: Revenue Expected to Fall.NEWS7: GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings.NEWS8: Novartis Launches FocalView to Modernize Clinical Trials.NEWS9: Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18.NEWS10: How Analysts Rate Bristol-Myers Squibb in 1Q18.NEWS11: A Review of Novo Nordisk’s Modern Insulin.NEWS12: Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18.NEWS13: Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?.NEWS14: Gilead Sciences has a Strong Oncology Research Program.NEWS15: Why Incyte Stock Fell ~9% on April 24.NEWS16: Novo Nordisk’s Xultophy Expected to See High Growth in 2018.NEWS17: How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18.NEWS18: Is Eli Lilly and Company a Buy?.NEWS19: Is Eli Lilly and Company a Buy?.NEWS20: Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease.NEWS21: Is Eli Lilly and Company a Buy?.
2018-04-26: NEWS1: How Analysts Rate JNJ after 1Q18 Earnings.NEWS2: Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates.NEWS3: What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?.NEWS4: Novo Nordisk’s Victoza Could See High Growth in 2018.
2018-04-27: NEWS1: Lilly to Participate in Bank of America Merrill Lynch Health Care Conference.NEWS2: How Did BioMarin Pharmaceutical Perform in 1Q18?.NEWS3: Eli Lilly’s 1Q18 Earnings: Human Pharmaceutical Products Segment.NEWS4: Eli Lilly’s 1Q18 Earnings by Segment.NEWS5: Allergan’s 1Q18 Estimates: Expect Growth in Revenues.NEWS6: Eli Lilly’s 1Q18 Earnings and Revenue Growth.NEWS7: Analyst Recommendations for Novo Nordisk in April.NEWS8: How Is Novo Nordisk Positioned before 1Q18?.

Answer: Decrease